NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor

NCT06040905

CompletedNA

Sponsor: Chung Shan Medical University

Conditions: Mild Cognitive Impairment, Alzheimer Disease, Hyperglycemia, Pre-sarcopenia

Interventions: Coenzyme Q10, Placebo

Countries: Taiwan

The aim of the study is to investigate the effects of coenzyme Q10 supplementation (150 mg twice daily; 300 mg/day for 12 weeks) on coenzyme Q10 status, glucose parameters, BDNF, myokines, and cognitive function in patients with mild cognitive impairment (MCI) or Alzheimer's disease (AD) and hyperglycemia, either without sarcopenia risk or with pre-sarcopenia/sarcopenia risk.

Eligibility overview

Sex: ALL

Age: 50 Years to 80 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Clinical diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease (AD).
* Hyperglycemia, defined as fasting plasma glucose ≥100 mg/dL or current use of glucose-lowering medication.
* Either without sarcopenia risk or with pre-sarcopenia/sarcopenia risk, as determined by calf circumference, handgrip strength, or muscle endurance.
* Ability to swallow tablets.

Exclusion Criteria:

* Cancer.
* Severe cardiac, pulmonary, hepatic, or renal disease.
* Severe disability or aphasia.
* Malnutrition (body weight change \>5% within one month).
* Current use of coenzyme Q10 supplements.
* Current warfarin therapy.

Locations (1)

Taichung, Taiwan